All In Biotech

Drug Trial Radar · NCT04129164

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)

Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

183

Actual

Start

Dec 9, 2019

Primary completion

Sep 1, 2022

Study completion Mar 10, 2023

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

Conditions

  • Sjögren's Syndrome

Interventions

  • VIB4920Drug

    Intravenous Dose 1.

  • PlaceboDrug

    Intravenous dose matched to VIB4920.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Population 1: Change From Baseline in ESSDAI at Day 169Time frame: Baseline and Day 169
  2. Population 2: Change From Baseline in ESSPRI at Day 169Time frame: Baseline and Day 169

Locations

62 sites in 12 countries. Site status is shown where the registry gives one.

  • Research Site

    Fullerton, California

  • Research site

    Upland, California

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Kansas City, Kansas

  • Research Site

    Baltimore, Maryland

  • Research Site

    Wheaton, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Salisbury, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research site

    Duncansville, Pennsylvania

  • Research Site

    Memphis, Tennessee

  • Research site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Research Site

    Bordeaux, France

  • Research Site

    Brest, France

  • Research Site

    Grenoble, France

  • Research Site

    Paris, France

  • Research Site

    Strasbourg, France

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Gyula, Hungary

  • Research Site

    Secunderabad, Andhra Pradesh, India

  • Research Site

    Ahmedabad, Gujarat, India

  • Research Site

    Bangalore, Karnataka, India

  • Research Site

    Pune, Maharshtra, India

  • Research Site

    Pune, Maharshtra, India

  • Research Site

    Bhubaneswar, Odisha, India

  • Research Site

    Chennai, Tamil Nadu, India

  • Research Site

    Pisa, Italy

  • Research Site

    Udine, Italy

  • Research Site

    Milan, Lambardia, Italy

  • Research Site

    Rome, Lazio, Italy

  • Research Site

    Brescia, Province Of Brescia, Italy

  • Research Site

    Perugia, Umbria, Italy

  • Research Site

    Mexico City, Mexico

  • Research Site

    Saltillo, Coahuila, Mexico

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.